Latest Period
Q2 2026
Security Snapshot
Xeris Biopharma Holdings, Inc. - Common Stock (XERS) Institutional Ownership
CUSIP: 98422E103
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2026
Institutions Reporting
239
Shares (Excl. Options)
108,210,729
Price
$7.92
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- XERS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 108,210,729
- Total 13F value
- $856,777,172
- Portfolio coverage rank
- 0%
- Share change
- +2,828,512
- Value change
- +$30,135,914
- Number of holders
- 239
- Shares outstanding
- 172,752,800
- SEC-reported price per share
- $8.80
- Insider filing price
- $8.80
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- XERS - Xeris Biopharma Holdings, Inc. - Common Stock is tracked under CUSIP 98422E103.
- 239 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 234 to 239 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $610,300,730 to $856,777,172.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 239 institutions filings for Q2 2026.
Security key
98422E103
Latest holder period
Q2 2026
13F holders
239
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
XERS full holder history
Xeris Biopharma Holdings, Inc. SEC filings
Xeris Biopharma Holdings, Inc. company facts
Xeris Biopharma Holdings, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98422E103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
XERS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $70,483,142 | 8,637,640 | Vanguard Capital Management | 30 Jun 2026 |
As of 30 Jun 2026, 239 institutional investors reported holding 108,210,729 shares of Xeris Biopharma Holdings, Inc. - Common Stock (XERS). This represents 63% of the company’s total 172,752,800 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.4% | 14,525,539 | +12% | 0% | $115,042,270 |
| D. E. Shaw & Co., Inc. | 4.5% | 7,804,758 | +0.2% | 0.04% | $61,813,683 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 7,340,229 | +5.1% | 0% | $58,134,614 |
| STATE STREET CORP | 2.8% | 4,821,566 | +3.5% | 0% | $38,186,803 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.7% | 4,718,183 | +10% | 0% | $37,374,872 |
| Nuveen, LLC | 2.5% | 4,385,141 | +50% | 0.01% | $34,730,316 |
| Rosalind Advisors, Inc. | 1.7% | 2,908,981 | -10% | 8.7% | $23,039,130 |
| Qube Research & Technologies Ltd | 1.7% | 2,893,749 | -30% | 0.03% | $22,918,492 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.5% | 2,626,208 | -1.5% | 0% | $20,799,567 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.4% | 2,365,103 | +8.9% | 0% | $18,731,616 |
| MORGAN STANLEY | 1.4% | 2,337,096 | -9.2% | 0% | $18,509,800 |
| Legal & General Group Plc | 1.2% | 2,012,792 | +5.5% | 0% | $15,941,313 |
| ARMISTICE CAPITAL, LLC | 1.1% | 1,958,702 | +2.6% | 0.43% | $15,512,920 |
| TWO SIGMA INVESTMENTS, LP | 1.1% | 1,885,503 | -2% | 0.01% | $14,933,184 |
| Parkman Healthcare Partners LLC | 1% | 1,807,621 | +5% | 1.5% | $14,316,358 |
| ALGERT GLOBAL LLC | 1% | 1,742,942 | +51% | 0.16% | $13,804,101 |
| NORTHERN TRUST CORP | 0.92% | 1,597,749 | +11% | 0% | $12,654,172 |
| GOLDMAN SACHS GROUP INC | 0.92% | 1,594,072 | -1.2% | 0% | $12,625,051 |
| AQR CAPITAL MANAGEMENT LLC | 0.89% | 1,540,985 | +11% | 0% | $12,204,601 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.86% | 1,492,367 | +9.8% | 0% | $11,819,547 |
| FEDERATED HERMES, INC. | 0.83% | 1,434,433 | +67% | 0.02% | $11,360,709 |
| BANK OF AMERICA CORP /DE/ | 0.81% | 1,397,050 | +60% | 0% | $11,064,636 |
| UBS Group AG | 0.75% | 1,300,913 | -21% | 0% | $10,303,231 |
| Ishara Investments LP | 0.71% | 1,230,000 | +20% | 7.4% | $9,741,600 |
| VANGUARD FIDUCIARY TRUST CO | 0.71% | 1,224,398 | +8% | 0% | $9,697,232 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 108,210,729 | $856,777,172 | +$30,135,914 | $7.92 | 239 |
| 2026 Q1 | 105,168,996 | $610,300,730 | +$15,510,457 | $5.80 | 234 |
| 2025 Q4 | 100,824,477 | $791,465,005 | +$25,604,813 | $7.85 | 225 |
| 2025 Q3 | 96,875,375 | $788,604,319 | +$58,407,551 | $8.14 | 228 |
| 2025 Q2 | 90,495,534 | $422,617,978 | +$16,622,096 | $4.67 | 200 |
| 2025 Q1 | 86,799,982 | $476,523,606 | +$123,713,876 | $5.49 | 199 |
| 2024 Q4 | 65,548,446 | $222,208,577 | +$5,693,687 | $3.39 | 161 |
| 2024 Q3 | 63,918,467 | $182,169,401 | +$11,712,690 | $2.85 | 143 |
| 2024 Q2 | 60,623,914 | $136,403,872 | +$57,516 | $2.25 | 132 |
| 2024 Q1 | 60,495,199 | $133,691,334 | +$1,259,202 | $2.21 | 140 |
| 2023 Q4 | 59,921,867 | $140,817,138 | +$3,980,290 | $2.35 | 118 |
| 2023 Q3 | 55,319,172 | $102,889,496 | -$2,383,422 | $1.86 | 109 |
| 2023 Q2 | 55,920,487 | $146,506,955 | +$17,809,976 | $2.62 | 101 |
| 2023 Q1 | 49,463,144 | $80,622,599 | -$5,927,964 | $1.63 | 89 |
| 2022 Q4 | 53,916,182 | $71,703,555 | -$5,395,029 | $1.33 | 93 |
| 2022 Q3 | 57,306,752 | $89,403,802 | -$3,332,109 | $1.56 | 97 |
| 2022 Q2 | 59,291,260 | $91,305,115 | +$12,225,836 | $1.54 | 95 |
| 2022 Q1 | 50,404,861 | $129,034,768 | +$23,839,809 | $2.56 | 97 |
| 2021 Q4 | 40,971,724 | $120,062,000 | +$117,961,261 | $2.93 | 85 |
| 2021 Q3 | 704,170 | $1,725,000 | +$1,725,000 | $2.45 | 1 |